Cosmos Health CFO granted 850K COSM shares
Cosmos Health Inc. Chief Financial Officer Georgios Terzis reported equity compensation involving 850,000 shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cosmos Health Inc. Chief Financial Officer Georgios Terzis reported equity compensation involving 850,000 shares. He received an award of 850,000 shares of Common Stock at $0.283 per share, granted on May 19, 2026 under the company’s 2024 & 2025 Omnibus Incentive Plan and exempt under Rule 16b-3.
On the same date, 850,000 Restricted Stock Units converted into an equal number of Common Stock shares, with the RSUs vesting immediately at grant and then being fully settled. Following these transactions, Terzis holds 2,067,263 Common Stock shares directly.
Insider Trade Summary
850,000 shares exercised/converted
Exercise
2 txns
Insider
Terzis Georgios
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Restricted Stock Unit | 850,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock, par value $.001 | 850,000 | $0.283 | $241K |
Holdings After Transaction:
Restricted Stock Unit — 0 contracts (Direct);
Common Stock, par value $.001 — 2,067,263 shares (Direct)
Footnotes (2)
- F1. Reflects the award of 850,000 shares of Common Stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3.
- F2. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.
Key Figures
Common Stock award: 850,000 shares
Award price per share: $0.283 per share
RSUs converted: 850,000 units
+4 more
7 metrics
Common Stock award
850,000 shares
Award of Common Stock granted May 19, 2026
Award price per share
$0.283 per share
Transaction price for 850,000 awarded Common Stock shares
RSUs converted
850,000 units
Restricted Stock Units converted into Common Stock on May 19, 2026
RSU exercise price
$0.0000
Conversion or exercise price for RSUs
Shares after transactions
2,067,263 shares
Total Common Stock directly owned by CFO after transactions
RSU grant date
May 19, 2026
Grant and vesting date under 2024 & 2025 Omnibus Incentive Plan
RSU expiration
May 19, 2036
Expiration date listed for RSU derivative security
Key Terms
Restricted Stock Unit, Omnibus Incentive Plan, Rule 16b-3, derivative security
4 terms
Restricted Stock Unit financial
"The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Omnibus Incentive Plan financial
"pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3"
An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.
Rule 16b-3 regulatory
"in a transaction exempt under Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
derivative security financial
"Conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cosmos Health (COSM) CFO report in this Form 4 filing?
The Cosmos Health CFO reported equity compensation transactions involving 850,000 shares of Common Stock. These came from an award and related RSU conversion under the 2024 & 2025 Omnibus Incentive Plan, recorded as acquisitions exempt under Rule 16b-3.
What happened to the 850,000 Restricted Stock Units in the COSM filing?
The 850,000 Restricted Stock Units were granted and vested on May 19, 2026, then converted into 850,000 Common Stock shares. After this conversion, the RSU position dropped to zero, meaning all of those units were fully settled into stock.
Under which plan were the Cosmos Health (COSM) awards granted?
The Common Stock and RSU awards were granted under Cosmos Health’s 2024 & 2025 Omnibus Incentive Plan. This plan governs equity-based compensation for executives and the transactions were reported as exempt from short-swing rules under Rule 16b-3.
Are the Cosmos Health (COSM) CFO’s transactions open-market buys or sales?
The transactions are not open-market buys or sales; they are compensation-related awards and a derivative conversion. The Form 4 classifies them as acquisitions through a grant and RSU conversion, both treated as exempt under Rule 16b-3, with no reported market trades.
AI-generated analysis. How Rhea-AI works. Not financial advice.
